Summary
Zoetis Inc. (ZTS) reported strong financial results for the third quarter and first nine months of 2021, demonstrating robust revenue growth and profitability. Revenue increased by 11% in the third quarter and 19% year-to-date, driven by both volume and price increases, with significant contributions from companion animal products and strong operational performance in international markets. The company's strategic focus on innovation and expansion into emerging markets continues to yield positive results. Profitability also showed significant improvement, with Net Income attributable to Zoetis Inc. growing by 15% for the quarter and 27% year-to-date. This growth was supported by effective cost management, though the company did experience some increases in operating expenses, such as SG&A and R&D, to support its growth initiatives and innovation pipeline. Zoetis maintained a healthy balance sheet and strong cash flow from operations, underscoring its financial stability and capacity for future investments and shareholder returns.
Financial Highlights
52 data points| Revenue | $1.99B |
| Cost of Revenue | $586.00M |
| Gross Profit | $1.40B |
| SG&A Expenses | $504.00M |
| Interest Expense | $56.00M |
| Net Income | $552.00M |
| EPS (Basic) | $1.16 |
| EPS (Diluted) | $1.16 |
| Shares Outstanding (Basic) | 474.00M |
| Shares Outstanding (Diluted) | 476.30M |
Key Highlights
- 1Revenue increased by 11% to $1.99 billion for the three months ended September 30, 2021, and by 19% to $5.81 billion for the nine months ended September 30, 2021.
- 2Net income attributable to Zoetis Inc. grew by 15% to $552 million for the third quarter and by 27% to $1.62 billion for the nine months ended September 30, 2021.
- 3Companion animal products showed strong growth, with revenue up 21% for the quarter and 31% year-to-date, driven by key parasiticide and dermatology products, as well as new monoclonal antibody therapies.
- 4International segment revenue grew 18% for the quarter and 25% year-to-date, with operational growth of 14% and 20% respectively, benefiting from strong companion animal sales and favorable foreign exchange.
- 5The company announced an agreement to acquire Jurox, an Australian animal health company specializing in companion animal and livestock veterinary medicines, expected to close in the first half of 2022.
- 6Diluted Earnings Per Share (EPS) increased by 16% to $1.16 for the third quarter and by 27% to $3.40 for the nine months ended September 30, 2021.
- 7Zoetis maintained strong liquidity, with cash and cash equivalents of $3.27 billion as of September 30, 2021, and positive cash flow from operations.